US Bancorp DE Sells 461,942 Shares of Pfizer Inc. $PFE

US Bancorp DE decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,259,362 shares of the biopharmaceutical company’s stock after selling 461,942 shares during the period. US Bancorp DE’s holdings in Pfizer were worth $108,529,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Catalyst Financial Partners LLC raised its holdings in shares of Pfizer by 6.1% in the 3rd quarter. Catalyst Financial Partners LLC now owns 17,922 shares of the biopharmaceutical company’s stock worth $457,000 after acquiring an additional 1,026 shares during the last quarter. Empirical Asset Management LLC increased its holdings in Pfizer by 13.6% during the 3rd quarter. Empirical Asset Management LLC now owns 12,310 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 1,472 shares in the last quarter. MAI Capital Management increased its holdings in Pfizer by 7.7% during the 3rd quarter. MAI Capital Management now owns 393,049 shares of the biopharmaceutical company’s stock worth $10,015,000 after purchasing an additional 28,163 shares in the last quarter. RWA Wealth Partners LLC lifted its holdings in shares of Pfizer by 2.3% in the third quarter. RWA Wealth Partners LLC now owns 237,439 shares of the biopharmaceutical company’s stock valued at $6,050,000 after purchasing an additional 5,231 shares in the last quarter. Finally, Cary Street Partners Financial LLC lifted its holdings in shares of Pfizer by 6.8% in the third quarter. Cary Street Partners Financial LLC now owns 261,861 shares of the biopharmaceutical company’s stock valued at $6,672,000 after purchasing an additional 16,705 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on PFE shares. Scotiabank assumed coverage on shares of Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective on the stock. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 price target on shares of Pfizer in a report on Wednesday, November 5th. UBS Group assumed coverage on shares of Pfizer in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price objective for the company. TD Cowen restated a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Finally, Bank of America reduced their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $27.70.

Pfizer Trading Up 0.1%

Shares of PFE opened at $27.11 on Friday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The business has a 50-day moving average of $26.08 and a 200 day moving average of $25.39. The firm has a market cap of $154.14 billion, a P/E ratio of 19.93 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The company’s revenue was down 1.2% on a year-over-year basis. During the same quarter last year, the company earned $0.63 earnings per share. As a group, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.3%. Pfizer’s dividend payout ratio is 126.47%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.